Company Overview - I-Mab is a US-based global biotech company focused on developing highly differentiated immunotherapies for cancer treatment [3]. Financial Results Announcement - I-Mab plans to release its financial results for the third quarter ended September 30, 2024, on November 14, 2024, before the market opens [1]. - The company will not host a conference call to discuss the third quarter financial results [2]. Future Communications - I-Mab intends to hold an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives [2].

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024. Event Details Meeting Date Thursday, November 7, 2024 Meetings One-on-one and small group meetings: November 7, 2024 Sean Fu, PhD ...

I-Mab Sponsored ADR (IMAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earning ...

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levelsThe recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study dosesA Phase 1b study, evaluating givastomig in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in fro ...

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025ROCKVILLE, Md., Sept. 10, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech com ...

I-MAB Biopharma (NASDAQ:IMAB) Q2 2024 Earnings Conference Call August 28, 2024 8:00 AM ET Company Participants Sean Fu - Chief Executive Officer (interim) Phillip Dennis - Chief Medical Officer Joseph Skelton - Chief Financial Officer Tyler Ehler - Vice President, Investor Relations Conference Call Participants Joe Catanzaro - Piper Sandler Unknown Analyst - Jefferies Andres Maldonado - HC Wainwright Operator Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conf ...

Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ETROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline ...

ROCKVILLE, Md., July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein, who steps down from I-Mab's Board of Directors and the Interim Chairperson position.  Mr. Wei Fu has served as a member of the I-Mab Board of Directors since June 2018 and is the Chief Executive Officer of CBC Group, a ...

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in a poster session scheduled for June 1, 2024 at 9:00 am CDT ROCK ...

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitorsPhase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in a poster session scheduled for June 1, 2024 at 9:00 am CDT ROCKV ...